Brand VerifiedUnited States

ResMed Inc.

ResMed

ResMed is the world's leading digital health technology company specializing in sleep apnea and respiratory care devices, founded in 1989 in San Diego, California, USA. With annual revenue of $5.1 billion, the company operates 8+ factories across 6 countries, employing over 10,000 people. ResMed's CPAP and BiPAP devices, combined with its myAir cloud platform, create a powerful ecosystem that sets

United StatesEst. 198910000+$5.1 Billion8+ factories in 6 countriesNYSE: RMDScore 92

Business Nature

ResMed is a vertically integrated medical device manufacturer that designs, develops, and manufactures its own CPAP/BiPAP devices, masks, and accessories in-house across 8+ facilities. The company operates both a wholesale distribution model to DME suppliers and a direct-to-consumer digital channel via myAir platform, creating a unique hardware+software closed-loop business model.

Core Business Areas

Sleep and Respiratory Care Devices – Core Business
• Flow generators, CPAP and BiPAP devices for obstructive sleep apnea treatment
• Masks, headgear, and consumable accessories with high recurring replacement demand
• myAir digital health platform for remote patient monitoring and compliance data
• Ventilators for home and hospital use across multiple respiratory conditions
• Cloud-connected sleep therapy management software suite
• Nasal and full-face mask portfolio with advanced seal technologies

Industry Rankings

2Top 10 Home Medical Devices Brands

Brand

Corporate Report

ResMed is a US-based digital health technology company headquartered in La Jolla, California. Founded in 1989. Revenue $5.1 billion, 10,000+ employees across 8+ factories in 6 countries.

Business Overview

ResMed dominates the global sleep apnea market with its CPAP and BiPAP devices, masks, and cloud-connected myAir platform. The company has benefited enormously from competitor Philips' regulatory setbacks, capturing significant market share in the US and globally.

Key Strengths

59.4% gross margin driven by high-margin consumable mask replacements; myAir platform with millions of daily active users creating sticky patient ecosystem; 28% operating profit growth in FY2025 showing strong operational leverage; diversified manufacturing across Australia, Singapore, and China reducing geopolitical risk.

Challenges & Outlook

Heavy reliance on sleep apnea as a single therapeutic category; potential disruption from GLP-1 weight-loss drugs reducing OSA prevalence; risk of Philips eventually returning to the US market after resolving regulatory issues.

VerityRank Score

92/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

La Jolla, California, USA

Founded

1989

Employees

10000+

Factories

8+ factories in 6 countries

Listing

NYSE: RMD

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: RMD

Back to Rankings